NCT02837978View on ClinicalTrials.gov

The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

December 30, 2022

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Tacrolimus

Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.

DRUG

MTX

MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.

Trial Locations (1)

250012

Qilu Hospital, Jinan

All Listed Sponsors
lead

Qiang Shu

OTHER

NCT02837978 - The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment | Biotech Hunter | Biotech Hunter